No insider purchase over the last 90 days. The latest was filed 16 Mar 2026.
Follow the MBX Biosciences, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €3.3bn. The latest transaction was reported on 17 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Hawryluk P. Kent. The full history is accessible without an account.
39
Insider Decl.
n/a
Thresholds
€12M
8 ops.
Buy Volume
€21,132
1 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate MBX Biosciences, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$88.40.
49Σ signal
Buys €12M€21,132 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
MBX Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for metabolic diseases. It is listed on NASDAQ under the ticker MBX.